 |
市场调查报告书
商品编码
1904453
HERG筛检市场规模、份额和成长分析（按类型、离子通道、应用和地区划分）—2026-2033 年产业预测HERG Screening Market Size, Share, and Growth Analysis, By Type (Gene KCNH2, Mutant KCNH2), By Ion Channel (Voltage-Gated, Ligand-Gated), By Application, By Region - Industry Forecast 2026-2033 |
||||||
预计到 2024 年，全球 HERG筛检市场规模将达到 17.9 亿美元，到 2025 年将达到 20 亿美元，到 2033 年将达到 48.8 亿美元，在预测期（2026-2033 年）内，复合年增长率为 11.8%。
全球HERG基因筛检市场正经历显着成长，其主要驱动力是人们对药物安全性的日益关注以及对更高效筛检方法的需求。製药和生技产业是这一趋势的关键促进者，它们寻求可靠的技术来降低药物诱发心律不整的风险。人们对药物心臟毒性的认识不断提高，凸显了HERG基因筛检在药物研发过程中的重要性。自动化膜片钳系统和高通量筛检等技术进步正在推动市场扩张。此外，严格的监管要求迫使製药公司投资HERG基因筛检以确保合规性。然而，先进筛检设备所需的高额初始投资对中小企业和研究机构构成了挑战。此外，准确预测心臟安全性仍然十分复杂，需要持续的研究。
全球HERG筛检市场驱动因素
对药物安全性的日益重视是全球HERG基因筛检市场的主要驱动力，促使各公司投入资源研发创新筛检技术。这项投资旨在在药物研发早期识别具有潜在心臟毒性风险的化合物。随着监管压力的增加和对安全药物需求的不断增长，各机构逐渐认识到有效HERG基因筛选在降低药物筛检风险的重要性。因此，对药物安全性的关注不仅推动了调查方法的进步，也提高了上市新型治疗化合物的整体疗效和可靠性。
限制全球HERG筛检市场的因素
全球HERG筛检市场面临的一大挑战是先进筛检设备（例如自动化膜片钳系统）的部署和维护成本高昂。这一巨大的经济障碍为中小型製药公司和研究机构带来了挑战，限制了它们获得尖端HERG基因筛检技术的机会。因此，这些机构可能会落后于能够更轻鬆地投资必要硬体和资源的大型竞争对手，最终影响它们在药物研发领域的创新和新药开发能力。这种经济限制可能会阻碍整体市场成长和关键筛检方法的进步。
全球HERG筛检市场趋势
随着越来越多的公司寻求高效的解决方案来评估药物安全性，全球HERG筛检市场正经历着向自动化和高通量技术的显着转变。消费者对洁净标示产品的日益关注，推动了对严格筛检流程的需求，以识别药物化合物中潜在的HERG风险。自动化膜片钳系统因其高通量和精确的测量能力而备受关注，能够实现更有效率的药物研发流程。这种对高通量筛检（HTS）技术的关注，使研究人员能够同时评估大量化合物，最终加速开发更安全的治疗方案，并加强业界的监管合规性。
目录
介绍
- 调查目标
- 调查范围
- 定义
调查方法
- 资讯收集
- 二手资料和一手资料方法
- 市场规模预测
- 市场假设与限制
执行摘要
- 全球市场展望
- 供需趋势分析
- 细分市场机会分析
市场动态与展望
- 市场规模
- 市场动态
- 驱动因素和机会
- 限制与挑战
- 波特分析
关键市场考察
- 关键成功因素
- 竞争程度
- 关键投资机会
- 市场生态系统
- 市场吸引力指数（2025）
- PESTEL 分析
- 总体经济指标
- 价值链分析
- 定价分析
- 案例研究分析
全球HERG筛检市场规模（按类型和复合年增长率划分）（2026-2033年）
- 基因 KCNH2
- 突变体KCNH2
全球HERG筛检市场规模（依离子通道及复合年增长率划分）（2026-2033年）
- 电压依赖性
- 配体依赖性
全球HERG筛检市场规模（依应用及复合年增长率划分）（2026-2033年）
- 抗心律不整药物
- 抗精神病药物
- 抗生素
- 其他的
全球HERG筛检市场规模（按地区划分）及复合年增长率（2026-2033年）
- 北美洲
- 美国
- 加拿大
- 欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
- 亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
- 拉丁美洲
- 巴西
- 其他拉丁美洲地区
- 中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区
竞争资讯
- 前五大公司对比
- 主要企业的市场定位（2025 年）
- 主要市场参与者所采取的策略
- 近期市场趋势
- 公司市占率分析（2025 年）
- 主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较
主要企业简介
- Cytocentrics AG（Germany）
- Charles River Laboratories（US）
- Thermo Fisher Scientific Inc.（US）
- PerkinElmer Inc.（US）
- Eurofins Scientific SE（Luxembourg）
- Nanion Technologies GmbH（Germany）
- SB Drug Discovery（UK）
- B'SYS GmbH（Switzerland）
- RedShift BioAnalytics, Inc.（US）
- Icagen, Inc.（a division of Eurofins DiscoverX）（US）
- Apredica（a division of Eurofins DiscoverX）（US）
- Inotrem SA（France）
- Axxam SpA（Italy）
- Ncardia AG（Germany）
结论与建议
Global HERG Screening Market size was valued at USD 1.79 Billion in 2024 and is poised to grow from USD 2 Billion in 2025 to USD 4.88 Billion by 2033, growing at a CAGR of 11.8% during the forecast period (2026-2033).
The global hERG screening market is experiencing significant growth driven by heightened focus on drug safety and the demand for more efficient screening methods. The pharmaceutical and biotechnology sectors are key contributors to this trend, as they seek reliable technologies to mitigate the risk of drug-induced cardiac arrhythmias. Increased awareness of drug cardiotoxicity has underscored the importance of hERG screening in the drug development process. Advances in technologies, including automated patch clamp systems and high-throughput screening, are propelling market expansion. Additionally, stringent regulatory demands urge pharmaceutical companies to invest in hERG screening to ensure compliance. However, the high initial investment for sophisticated screening equipment poses a challenge for smaller companies and research institutions, while accurately predicting cardiac safety remains complex, necessitating ongoing research.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global HERG Screening market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global HERG Screening Market Segments Analysis
Global HERG Screening Market is segmented by Type, Ion Channel, Application and region. Based on Type, the market is segmented into Gene KCNH2 and Mutant KCNH2. Based on Ion Channel, the market is segmented into Voltage-Gated and Ligand-Gated. Based on Application, the market is segmented into Antiarrhythmic, Antiphyshotic, Antibiotics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global HERG Screening Market
The growing focus on ensuring drug safety serves as a primary catalyst for the Global HERG Screening market, prompting companies to allocate resources toward innovative screening technologies. This investment is aimed at identifying potential compounds that may have adverse cardiac effects early in the drug discovery process. As regulatory pressures increase and the demand for safe pharmaceuticals rises, organizations recognize the importance of effective HERG screening in mitigating risks associated with drug development. Consequently, this emphasis on drug safety not only fosters advancements in screening methodologies but also enhances the overall efficacy and reliability of new therapeutic compounds entering the market.
Restraints in the Global HERG Screening Market
A significant challenge facing the Global HERG Screening market is the high cost associated with obtaining and maintaining advanced screening equipment, such as automated patch clamp systems. This substantial financial hurdle poses difficulties for smaller pharmaceutical companies and research institutions, limiting their access to cutting-edge hERG screening technologies. As a result, these organizations may struggle to keep pace with larger competitors that can more easily invest in necessary hardware and resources, ultimately impacting their capacity for innovation and research within the field of drug development. Such economic constraints can restrict overall market growth and the advancement of critical screening methodologies.
Market Trends of the Global HERG Screening Market
The Global HERG Screening market is experiencing a significant trend towards automation and high-throughput technologies, as companies increasingly seek efficient solutions for assessing drug safety profiles. The rising consumer awareness of clean label products has heightened the demand for rigorous screening processes to identify potential hERG liabilities in pharmaceutical compounds. Automated Patch Clamp Systems are gaining traction due to their capability for high throughput and precise measurements, streamlining the drug discovery workflow. This focus on High-Throughput Screening (HTS) technology enables researchers to evaluate numerous compounds simultaneously, ultimately accelerating the development of safer therapeutic options and enhancing regulatory compliance in the industry.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2025
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
- Case Study Analysis
Global HERG Screening Market Size by Type & CAGR (2026-2033)
- Market Overview
- Gene KCNH2
- Mutant KCNH2
Global HERG Screening Market Size by Ion Channel & CAGR (2026-2033)
- Market Overview
- Voltage-Gated
- Ligand-Gated
Global HERG Screening Market Size by Application & CAGR (2026-2033)
- Market Overview
- Antiarrhythmic
- Antiphyshotic
- Antibiotics
- Others
Global HERG Screening Market Size & CAGR (2026-2033)
- North America (Type, Ion Channel, Application)
- US
- Canada
- Europe (Type, Ion Channel, Application)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Type, Ion Channel, Application)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Type, Ion Channel, Application)
- Brazil
- Rest of Latin America
- Middle East & Africa (Type, Ion Channel, Application)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Cytocentrics AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Charles River Laboratories (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PerkinElmer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eurofins Scientific SE (Luxembourg)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Nanion Technologies GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- SB Drug Discovery (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- B'SYS GmbH (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- RedShift BioAnalytics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Icagen, Inc. (a division of Eurofins DiscoverX) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Apredica (a division of Eurofins DiscoverX) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Inotrem S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Axxam S.p.A. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ncardia AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
